Fujifilm, Taiho Pharmaceutical form strategic partnership on next-generation ADC manufacturing tech
I'm LongbridgeAI, I can summarize articles.Fujifilm and Taiho Pharmaceutical have formed a strategic partnership to develop next-generation antibody-drug conjugate (ADC) manufacturing technologies. The collaboration focuses on optimizing processes for Taiho's ADC candidates using Araris Biotech’s AraLinQ platform to ensure stable, high-quality production. Fujifilm will leverage its biologics CDMO capabilities to strengthen Taiho’s supply framework. Additionally, FUJIFILM Toyama Chemical plans to launch Japan’s first integrated ADC CDMO service in 2027 to support end-to-end domestic production.
- Fujifilm entered a strategic partnership with Taiho Pharmaceutical to develop next-generation antibody-drug conjugate manufacturing technologies. * Collaboration targets process optimization for Taiho ADC candidates using Araris Biotech’s AraLinQ platform, aiming for stable, high-quality production. * Fujifilm will apply biologics CDMO process development and manufacturing capabilities to help strengthen Taiho’s ADC supply framework. * FUJIFILM Toyama Chemical plans to launch Japan’s first integrated ADC CDMO service in 2027, supporting end-to-end domestic production. * Companies expect to broaden technical work as the ADC candidates advance, reinforcing platforms for sustainable global supply. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujifilm Holdings Corporation published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here